Kyverna Therapeutics reported positive registrational‑scale results for its autologous CD19 CAR‑T in stiff person syndrome (SPS), an autoimmune neurological disorder with no approved therapies. The company said the trial met its primary and secondary endpoints and plans a U.S. regulatory submission in the first half of 2026. Kyverna’s readout marks one of the first late‑stage successes for CAR‑T approaches in autoimmune disease and could establish a regulatory pathway for cell therapies targeting non‑oncology indications.